GFAP and neoplasm: Furthermore, administration of specific treatments affecting T-cell regulation such as immune checkpoint inhibitors (ipilinumav, nivolumab) for the treatment of neoplasms or the anti-CD25 monoclonal antibody daclizumab, which was, for a short period of time, used for the treatment of multiple sclerosis (MS), has been associated with cases of GFAP astrocytopathy [2,12,17].